Acrid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acrid

Quick Facts

Property Description
Active ingredient Pantoprazole (as Pantoprazole sodium sesquihydrate)
Form Enteric-coated tablet, Intravenous injection
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Control and reduction of gastric acid secretion
Origin Synthetic (Substituted Benzimidazole derivative)

Acrid: Defining the Single-Ingredient Medicine

Acrid is a prescription-only medicine containing the sole active substance, Pantoprazole, typically formulated as Pantoprazole sodium sesquihydrate. Chemically, Pantoprazole is a synthetic compound derived from the substituted benzimidazole class. This single-ingredient product focuses its entire therapeutic action on one specific target, aiming for a defined and predictable effect in controlling internal acid levels. Acrid is clinically recognized for its specificity and stability.


What Type of Drug Is Acrid (Pantoprazole)?

Acrid is pharmacologically classified as a Proton Pump Inhibitor (PPI), a specialized group of agents used for the profound and sustained control of acid output from the stomach. The mechanism of this drug achieves durable suppression of acid secretion. This action allows the body to maintain a state of low acidity, essential for the healing process. Acrid is available in forms suitable for different applications, including the enteric-coated tablet for oral administration and a solution for intravenous injection (parenteral administration). The enteric coating is a vital design feature, as it protects the acid-sensitive Pantoprazole from being prematurely deactivated in the stomach.


How Acrid Helps Control Excessive Gastric Acid

The overall purpose of Acrid is to establish a less acidic environment within the upper digestive tract by effectively reducing the volume of acid produced. The Pantoprazole achieves this by engaging in an irreversible blockade of the final stage of acid creation, targeting the H+/K+-ATPase enzyme, commonly known as the Proton Pump. By diminishing both baseline and stimulated acid secretion, the medicine helps manage symptoms related to excessive gastric acid by providing consistent anti-secretory control.

What side effects are possible with Acrid?

Official Safety Profile and Adverse Reactions

The possible adverse reactions associated with Acrid (Pantoprazole) are documented in regulatory labeling and categorized by their frequency of occurrence, based on clinical trial data and post-marketing surveillance. This classification system, used by government health authorities, organizes effects into tiers such as Common, Uncommon, Rare, and Very Rare.

Officially listed Common side effects typically include gastrointestinal disturbances like diarrhea, flatulence, nausea, and abdominal pain, along with effects on the nervous system such as headache and dizziness. Uncommon reactions may involve sleep disorders, rash, or malaise. Rarer, but documented, effects include certain blood disorders like agranulocytosis.

Serious Adverse Reactions and Systemic Safety

Official documents list several Serious Adverse Reactions, which, while often rare, are clinically significant. These include severe allergic reactions (anaphylaxis), acute kidney inflammation (acute interstitial nephritis), and severe skin conditions (such as Stevens-Johnson syndrome). The medicine is also noted to slightly increase the risk of gastrointestinal infections, including Clostridioides difficile-associated diarrhea.

Exposure-Related and Population-Specific Safety

Safety statements from regulatory agencies also address risks associated with the duration of use. Long-term therapy (generally exceeding one year) is associated with an increased risk of bone fracture, particularly in older adults, and potential deficiency of Vitamin B12. Additionally, use in patients with severe hepatic impairment requires regular monitoring of liver enzyme levels, as noted in the Summary of Product Characteristics (SmPC). These duration and population-specific notes define the constraints for the medicine's prolonged use.

Overdose and Emergency Response

Acrid Overdose and when to seek help

Overdose Manifestations and Treatment

Clinical experience with Acrid doses exceeding 240 mg is documented as limited. Regulatory documentation states that spontaneous reports of overdose events are generally observed to be within the known safety profile of the medicine. Treatment is officially mandated to be symptomatic and supportive. No specific antidote for Acrid overdose is known to exist, and the substance is not removed by hemodialysis.

Official Management Status Description
Antidote Availability No specific antidote exists.
Procedural Note The substance is not removed by hemodialysis.
Management Protocol Treatment must be symptomatic and supportive.

When Urgent Medical Help is Required

Seeking immediate medical attention is a required action for any suspected overdose. Government health authorities explicitly mandate calling emergency services (911/national equivalent) if severe or life-threatening manifestations occur.

These specific conditions include:

  • Experiencing a seizure.
  • Collapse or inability to remain conscious.
  • Significant trouble breathing.
  • Inability to be awakened.

For other suspected overexposures, contact a national Poison Control Center (e.g., 1 -800 -222 -1222) immediately for guidance, even if symptoms are not present.

Connection to the Overall Overdose Profile

The official regulatory profile for Acrid emphasizes the requirement for symptomatic and supportive care, as specific medical procedures like hemodialysis are ineffective, and no antidote is available. This profile dictates that the immediate action for severe clinical signs is to contact emergency services, adhering strictly to official help-seeking protocols.

Therapeutic Uses of Acrid

Acrid is applied across domains where additional symptomatic support is needed.

Promoting Management and Repair of Injured Tissues

Acrid is commonly used to help with the symptomatic management and repair of injured tissues, including erosive esophagitis associated with inflammatory or irritative states due to acid, and may be part of regimens for gastric and duodenal ulcers. The therapeutic benefit is associated with reducing the acidity level, which is considered relevant for the body's repair processes when symptoms are related to inflammatory or irritative states. This medicine is relevant in situations where supportive symptom management is appropriate for conditions involving inflammatory processes.


Symptomatic Relief for Chronic Reflux (GERD) Manifestations

The medicine is commonly used to help with symptomatic relief for chronic Gastroesophageal Reflux Disease (GERD). It assists with managing the persistent, distressing symptom clusters of frequent heartburn (pyrosis) and acid regurgitation, which may interfere with daily functioning. This management provides support that helps ease the overall symptom burden and may assist with maintaining functional stability. The primary conditions Acrid is applied to address are erosive esophagitis, Gastroesophageal Reflux Disease, and pathological hypersecretory conditions.


Addressing Symptoms of Pathological Acid Overproduction

Acrid is relevant in conditions marked by heightened symptoms of acid output, such as in Zollinger-Ellison Syndrome (ZES). In these cases, the medication provides support that contributes to maintaining functional stability when symptoms are more noticeable.


Quick Fact Block

Quick Fact: Relief for Persistent Acidity Description
Primary Focus Sustained reduction of gastric acid output
Symptom Cluster Heartburn, acid regurgitation, epigastric discomfort
Key Benefit Contributes to easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus Drug Information on Pantoprazole

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility information for Acrid, strictly based on regulatory documents.

Populations That Must Not Use Acrid (Contraindications)

Acrid is contraindicated and must not be used by patients with a known hypersensitivity or allergy to the active substance or any of the components of the product. Additionally, due to a component drug's composition, it is contraindicated in patients with a known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), specifically those with the syndrome of asthma, rhinitis, and nasal polyps.

Restrictions and Special Considerations

  • Organ Impairment: Use is not recommended in patients with moderate or severe renal impairment or moderate or severe hepatic (liver) impairment.
  • Pediatric Use: Safety and effectiveness have not been established in pediatric patients below the age of 6 months or those weighing less than 7 kg. The medicine must not be used in children or teenagers with viral infections because of the risk of Reye syndrome, a life-threatening condition associated with a component.
  • Older Adults: While no specific age-related contraindication exists, special consideration should be given to patients aged 65 years and older due to the higher possibility of age-associated renal and hepatic function abnormalities.

Summary of Regulatory Eligibility: The official labeling for Acrid defines who cannot use the drug by establishing formal contraindications based on known allergies, as well as specific restrictions for children and teenagers with viral infections. It further outlines that use is explicitly not recommended for patients with moderate or severe kidney or liver impairment.

What should I know about interactions with other medicines?

Acrid’s officially documented interaction profile is structured around two primary regulatory concerns: pharmacodynamic effects resulting from its acid suppression, and pharmacokinetic effects altering drug exposure. Co-administration with the antiretroviral agents atazanavir and nelfinavir is officially contraindicated or not recommended due to the risk of significantly reduced plasma concentrations and subsequent loss of efficacy.

The rise in gastric pH decreases the oral absorption and exposure of medicines whose bioavailability is acid-dependent, including antifungal azoles ( ketoconazole, itraconazole) and certain tyrosine kinase inhibitors. For patients co-administered warfarin or other coumarin anticoagulants, close monitoring of INR and prothrombin time is required due to documented changes in exposure.

Regulatory guidance further notes that temporary withdrawal of Acrid should be considered for patients receiving high-dose methotrexate to manage the risk of elevated serum concentrations. Long-term daily use is officially associated with potential vitamin B12 malabsorption. The medicine may also cause false-positive results on some urine screening tests for Tetrahydrocannabinol ( THC), a fact explicitly stated in regulatory documents.

Mechanism of Action

Irreversible Blockade of the Proton Pump

The primary mechanism of Acrid is the targeted and irreversible inhibition of the H^+/ K^+-ATPase (Proton Pump) enzyme in the gastric parietal cells. The drug is a pro-drug that undergoes acid-catalyzed conversion in the highly acidic canaliculi ( pH < 4) to form its active sulfenamide metabolite. This metabolite then creates a covalent bond with specific cysteine residues on the pump, physically blocking the final step of acid secretion. This action establishes a sustained reduction in secretion by structurally deactivating the machinery responsible for acid output.

Mechanism-Driven Duration

The duration of Acrid's physiological effect is determined by the natural half-life of the H^+/ K^+-ATPase enzyme (approximately 18–24 hours), which is distinct from the drug's plasma clearance time. Since the blockade is irreversible, new acid-secreting capacity only returns as the parietal cell synthesizes and inserts fresh Proton Pumps, ensuring a sustained suppression of basal and stimulated acid secretion.

Dosage and Administration Information

Administration Overview

Acrid is typically administered under the supervision of a healthcare professional in a clinical setting. The medication is provided as a solution intended for intravenous infusion. The process involves a slow drip into a vein, which allows the medication to enter the bloodstream directly.

Preparation and Setting

Before the procedure begins, a healthcare provider will prepare the necessary equipment and ensure the environment is appropriate for an infusion. Patients are usually seated or lying down comfortably during the duration of the administration.

Monitoring During Use

During the administration of Acrid, healthcare providers monitor the patient's vital signs and general response to the medication. This observation is a standard part of the protocol to ensure the process remains controlled and the patient remains comfortable throughout the infusion period.

Frequency and Duration

The schedule for Acrid administration is determined based on individual clinical assessment. Each session has a specific duration, which may vary depending on the specific requirements of the treatment plan. The timing between sessions is also established as part of a broader management strategy.

Recent Clinical Evidence

Research evidence / Overview of studies for Acrid (Pantoprazole)


Evidence for Short-Term Treatment of Erosive Esophagitis (EE)

Acrid was studied for outcomes related to physical discomfort used in research exploring short-term symptom changes for Erosive Esophagitis (EE). Researchers utilized randomized controlled trials (RCTs) to examine patient-reported experiences, often comparing Acrid against a placebo or against other acid-reducing agents.

Research explored outcomes related to anatomical status (monitored by endoscopy) and patient-reported outcomes describing perceived discomfort, such as the frequency and intensity of heartburn and regurgitation. Studies report how symptoms evolved in the observed populations, documenting the proportion of participants whose esophageal lining status changed within the defined 4- to 8-week assessment periods.


Evidence for Maintenance of Healing in Erosive Esophagitis

Acrid was studied for outcomes reflecting daily functioning or activity level in long-term observational settings after initial healing of EE, often using intermediate-term maintenance trials. The research examined patient-reported outcomes describing perceived discomfort, focusing on monitoring anatomical status in adults whose EE had been previously healed. Controlled maintenance studies typically monitored responses for up to one year.


Evidence for Pathological Hypersecretory Conditions (Zollinger-Ellison Syndrome)

Acrid was studied for outcomes related to systemic or functional imbalance, specifically in conditions marked by functional limitations, such as Zollinger-Ellison Syndrome (ZES). The critical outcomes measured involved outcomes related to systemic or functional imbalance, specifically monitoring acid output (Basal Acid Output or BAO). Findings describe group patterns, not personal outcomes, due to the use of small populations in these non-comparative studies.


What is Still Uncertain About the Research for Acrid

While extensive evidence exists for short-term use in adults, long-term effects are not fully established through controlled studies, and research exploring continuous use over multiple years is limited to observational data. Comparative evidence is lacking for follow-up durations extending beyond one year. Also, data for certain groups remain insufficient, and research in pediatric populations was primarily gathered from short-term studies, meaning follow-up durations were limited for the outcomes in children.

Key Studies & References

  1. 25 Years of Proton Pump Inhibitors: A Comprehensive Review (Class Review, Long-term and Maintenance Context)

Frequently Asked Questions (FAQ)

Common questions about Acrid (FAQ)

Q: What is the main reason doctors prescribe Acrid?

A: Regulatory documents state that this medicine is indicated for conditions related to excessive stomach acid. The primary approved uses include the healing and maintenance of Erosive Esophagitis (damage to the food pipe from acid reflux), and for managing Pathological Hypersecretory Conditions, such as Zollinger-Ellison Syndrome (ZES).


Q: Is Acrid used for conditions other than the primary one mentioned?

A: Yes, official product information indicates that the medicine is also described for the short-term treatment of symptoms associated with Gastroesophageal Reflux Disease (GERD). It is additionally approved for the long-term maintenance of healing after initial treatment of Erosive Esophagitis.


Q: Is it normal to feel tired after starting Acrid?

A: In post-marketing reports, tiredness has been described as a common side effect. Less common side effects reported in official documents include malaise, which is a general feeling of discomfort or being unwell, and fatigue.


Q: Does Acrid interact with common over-the-counter pain relievers?

A: The official drug label details specific interactions with certain prescription medications. It describes that the medicine’s mechanism of reducing stomach acid can potentially affect the absorption of other drugs whose bioavailability is dependent on gastric pH. Specific interactions with common over-the-counter pain relievers are not explicitly detailed in the regulatory text.


Q: Are there any specific vitamins or supplements that should not be taken with Acrid?

A: Official warnings note that daily long-term use, typically exceeding three years, may be associated with malabsorption of Vitamin B12 (Cyanocobalamin). For patients using the medicine for long durations, monitoring of B12 levels may be considered by a healthcare provider.


Q: Is it safe to drink alcohol while taking Acrid?

A: Clinical studies conducted on drug interactions found no clinically relevant interaction between this medicine and ethanol (alcohol). Information about individual circumstances is best discussed with a healthcare professional.


Q: What kind of foods or drinks interact with Acrid?

A: According to the official administration instructions, the tablets may be taken with or without food. Regulatory information also states that taking antacids does not impact how the delayed-release tablets are absorbed by the body.


Q: How long does it typically take for Acrid to start working?

A: Studies indicate that the onset of action is relatively rapid. The maximum effect of reducing stomach acid output is typically described as being reached between two and six hours after the medicine is administered.


Q: Do I need to take Acrid at a specific time of day?

A: For most commonly treated conditions, the medicine is generally administered once daily. Some regulatory guidance describes that the medicine is administered approximately 30 minutes before a meal for specific dosage forms and conditions.


Q: Can people with a history of heart issues be prescribed Acrid?

A: Official warnings address a risk of low magnesium levels (hypomagnesemia) associated with long-term use. This condition has been linked to serious events, including irregular heart rhythms (arrhythmias). Monitoring by a healthcare professional may be considered for patients predisposed to magnesium imbalances.


Q: Has Acrid been studied in different racial or ethnic groups?

A: Regulatory guidance and trial protocols for the medicine included requirements to gather information about patient populations. This covered the representation of ethnic and racial minorities within the groups studied during clinical development.


Q: Why is Acrid not suitable for children?

A: Official labeling states that the safety and effectiveness of the medicine have not been established in children younger than six months of age. Furthermore, its use is contraindicated, or forbidden, in children and teenagers who have viral infections due to the reported risk of Reye syndrome.


Q: Does Acrid cause weight gain or weight loss?

A: While not listed as a common reaction in clinical trials, both weight gain and weight loss have been noted in post-marketing experience. These are instances reported after the drug has become available to the public.


Q: Is Acrid available as a generic medicine?

A: Yes, the active ingredient, Pantoprazole, has been approved by the FDA in generic formulations. These generic versions are available for both the delayed-release tablets and the intravenous injection form.


Q: What should I do if a side effect is bothering me?

A: The official patient counseling information suggests contacting a doctor for medical advice about side effects. This guidance applies whether the side effect is minor or if symptoms that suggest a serious adverse event are experienced.


Q: Does Acrid interact with birth control pills?

A: Clinical drug interaction studies have determined that the medicine does not have a significant effect on the kinetics, or activity, of oral contraceptives. The official product label reflects this finding.


Q: Can Acrid affect my ability to drive or operate machinery?

A: The medicine can be associated with adverse reactions that may impair attention, such as dizziness and visual disturbances. The official safety information describes that effects such as these may impact the ability to drive or operate machinery.


Q: Does Acrid help with mood or anxiety?

A: This medicine is indicated for conditions related to gastric acid control, not for psychiatric conditions. However, regulatory documents mention that psychiatric side effects, including depression and anxiety, have been reported rarely in post-marketing experience.


Q: What is the purpose of the black box warning on Acrid (if applicable)?

A: The medicine does not currently carry an FDA Black Box Warning, which is the most severe type of regulatory caution. The official labeling does, however, include specific Warnings and Precautions for serious risks such as acute kidney inflammation, bone fracture, and Clostridium difficile associated diarrhea.


Q: Can Acrid be used during pregnancy, according to official data?

A: Available observational data from studies in human pregnancy do not suggest an association between use and major birth defects or other adverse outcomes. The official labeling describes the need to consider the potential benefit versus the potential risk to the fetus.


Q: Does Acrid have a risk of withdrawal symptoms?

A: While the specific term 'withdrawal symptoms' is not explicitly used, regulatory guidance notes that abrupt discontinuation of the medicine is sometimes linked to a risk of rebound acid hypersecretion (an increase in stomach acid production).


Q: How is the dose of Acrid typically adjusted?

A: Official product information states that dosing is adjusted based on the specific condition being treated. For chronic conditions marked by functional imbalance, such as Zollinger-Ellison Syndrome (ZES), the dose is individually adjusted based on acid output measurements.


Q: Why do official documents mention a specific patient population for Acrid?

A: Regulatory documents must specify certain populations (e.g., pediatric patients, those with liver impairment) to address differences in drug efficacy, safety, or how the body handles the medicine. This is done due to either limited research data or an increased possibility of adverse events in those groups.

How should Acrid be stored and disposed of?

How to Store and Dispose of Acrid

Acrid (Pantoprazole) must be stored and handled according to the following official regulatory requirements to ensure product stability and safety.

Storage Conditions

Acrid tablets must be stored at controlled room temperature between 20 C and 25 C (68 F and 77 F). The medicine must be protected from moisture and kept in its original, tightly closed container.

The injectable form (IV powder) must be stored below 25 C. Once the IV solution is prepared, it must be administered within 24 hours.

All forms of Acrid must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Acrid should be disposed of via a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt) and placed in a sealed bag before being thrown into the household trash. Do not flush the medicine down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acrid found in:

A-Z Index: